Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Epistem Announces Further Partnership With The University of Manchester

Published: Tuesday, April 22, 2014
Last Updated: Tuesday, April 22, 2014
Bookmark and Share
Partnership will allow the Company to expand its existing range of wound healing models.

Epistem Holdings Plc has announced a further partnership with The University of Manchester to further the understanding of the biology of chronic delayed wound healing associated with skin ulcers.

The team, led by Dr Matthew Hardman have been awarded an MRC Industry Collaboration Agreement (MICA) grant from the UK Medical Research Council to help fund the investigations. Chronic delayed wound healing is most often found in the elderly and those with diabetes.

Due to the increasingly aged population and rising incidence of diabetes the frequency of chronic wounds is increasing. However, there are very limited treatments available. The research, which investigates the role of specific inflammatory mediators produced by macrophages, is intended to lead to new preclinical models to evaluate potential new therapies in this area, as well as generate new therapeutic opportunities.

Dr Hardman is a world-leading expert in the molecular and cellular aspects of pathological healing and heads a multi-disciplinary research group within the Manchester Healing Foundation Centre for Tissue Regeneration at the University. Epistem's Contract Research Services Division provides specialized preclinical and scientific research services to drug development and personal care companies in the areas of oncology, mucositis, inflammation (inflammatory bowel disease and rheumatoid arthritis), wound healing and skincare. Epistem are experienced in commercializing new technologies and the partnership will allow the Company to expand its existing range of wound healing models.

Dr Hardman, who is based in the University's Faculty of Life Sciences, said: "It is a real privilege to be awarded this collaborative grant sponsored by the Medical Research Council. This partnership represents a tremendous opportunity to realize the potential of our work."

Catherine Booth, Managing Director at Epistem, added: "We are delighted to be working with Dr Hardman again, who is a highly regarded wound healing expert, and to be able to provide our customers with access to cutting edge preclinical models."

Epistem will be giving two oral presentations on recent additions to its wound healing portfolio at The Symposium on Advanced Wound Care (SAWC) on Thursday 24th April.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Epistem and CRT Announce Agreement
Agreement for the use of patient derived leukemic Primagraft samples.
Friday, May 01, 2015
Epistem Announces the Successful Evaluation of New RNA-AMP™ Technology
A highly sensitive and reproducible method to derive cDNA from picogram to nanogram quantities of RNA.
Friday, February 13, 2015
Epistem, Global Health Investment Fund Sign Collaborative Funding Agreement
Agreement will see GHIF support the roll-out of Epistem's Genedrive® molecular diagnostic platform.
Wednesday, July 23, 2014
Epistem Announces Opening of US Laboratory
Laboratory will support the expansion of Epistem's contract research division.
Thursday, March 06, 2014
Epistem Announces Executive Board Appointments
Dr Allan Brown joins the Board as Chief Operating Officer of the Diagnostics division of the Company, with effect from 1st February, 2014.
Monday, January 27, 2014
Epistem Announces Evaluation of Genedrive® for Pathogen Detection
Epistem in cooperative agreement with the US Air Force and with Johns Hopkins University.
Thursday, January 16, 2014
UK-Norwegian Collaboration Aims to Develop a New Living Skin Equivalent Model
New in vitro human living skin equivalent model for testing inflammatory responses.
Tuesday, May 21, 2013
Epistem Tuberculosis Test Gains CE-IVD Registration
Epistem to place its TB test and Genedrive™ units for sale in the EEA member state markets.
Thursday, July 05, 2012
Epistem Announces Collaboration with GSK
Three year biomarker collaboration in the field of fibrosis research.
Wednesday, March 14, 2012
Epistem Signs Tuberculosis Channel Partner Agreement
Company signs sales and marketing agreement for rapid molecular test for TB.
Tuesday, March 06, 2012
Epistem Holdings Announce £2.8 Million Cash Placing
Company to use the net proceeds to accelerate the development and commercialization of Genedrive™.
Tuesday, November 29, 2011
Epistem Announces Partnership with The University of Manchester
Partnership will allow Epistem to expand its wound healing models range.
Monday, November 14, 2011
Epistem Announces Collaboration With Sanofi-Aventis
3 year collaboration to provide discovery through to clinical biomarker support to oncology programmes of sanofi-aventis and its affiliates.
Monday, March 21, 2011
Epistem Presents its new Ex Vivo Plucked Hair Biomarker Assay at EORTC-NCI-AACR Symposium
New method for maintaining plucked human hairs ex vivo, and treating with therapeutic agents to obtain information on the cellular response to drug treatment.
Friday, November 19, 2010
EpiStem Awarded Further Long Term Funding for NIH Biodefence Programme
The Company has been reappointed for up to five years to provide preclinical testing services as a subcontractor.
Wednesday, November 10, 2010
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Fat Cells Originating from Bone Marrow Found in Humans
Cells could contribute to diabetes, heart disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos